1. Home
  2. RPRX vs CNA Comparison

RPRX vs CNA Comparison

Compare RPRX & CNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • CNA
  • Stock Information
  • Founded
  • RPRX 1996
  • CNA 1853
  • Country
  • RPRX United States
  • CNA United States
  • Employees
  • RPRX N/A
  • CNA N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • CNA Property-Casualty Insurers
  • Sector
  • RPRX Health Care
  • CNA Finance
  • Exchange
  • RPRX Nasdaq
  • CNA Nasdaq
  • Market Cap
  • RPRX 14.2B
  • CNA 13.3B
  • IPO Year
  • RPRX 2020
  • CNA N/A
  • Fundamental
  • Price
  • RPRX $31.13
  • CNA $50.81
  • Analyst Decision
  • RPRX Strong Buy
  • CNA Sell
  • Analyst Count
  • RPRX 5
  • CNA 2
  • Target Price
  • RPRX $41.60
  • CNA $50.50
  • AVG Volume (30 Days)
  • RPRX 4.3M
  • CNA 416.9K
  • Earning Date
  • RPRX 05-08-2025
  • CNA 05-05-2025
  • Dividend Yield
  • RPRX 2.83%
  • CNA 7.44%
  • EPS Growth
  • RPRX N/A
  • CNA N/A
  • EPS
  • RPRX 1.91
  • CNA 3.52
  • Revenue
  • RPRX $2,263,576,000.00
  • CNA $14,270,000,000.00
  • Revenue This Year
  • RPRX $33.46
  • CNA $7.41
  • Revenue Next Year
  • RPRX $4.44
  • CNA $6.18
  • P/E Ratio
  • RPRX $16.28
  • CNA $14.44
  • Revenue Growth
  • RPRX N/A
  • CNA 7.30
  • 52 Week Low
  • RPRX $24.05
  • CNA $42.33
  • 52 Week High
  • RPRX $34.20
  • CNA $52.36
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 33.61
  • CNA 61.51
  • Support Level
  • RPRX $32.26
  • CNA $48.83
  • Resistance Level
  • RPRX $34.14
  • CNA $51.34
  • Average True Range (ATR)
  • RPRX 0.76
  • CNA 0.83
  • MACD
  • RPRX -0.33
  • CNA 0.22
  • Stochastic Oscillator
  • RPRX 14.00
  • CNA 87.29

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About CNA CNA Financial Corporation

CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property and casualty products to small businesses and medium scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.

Share on Social Networks: